a.danu™ is a prescription cognitive, emotional, behavioral therapeutic for female patients diagnosed with oncologic disease within the past twelve months.
This cancer supportive care Rx therapeutic is agnostic to cancer type, location or treatment regimen.
This personalized treatment provides a fluid, distinctive capabilities strategy for cancer patients that blends participatory medicine with interactive digital technology. This medical intervention expands patient engagement beyond superficial adaption by utilizing the patients personal digital inputs to inform and transform their personal output (self modulation).
The clinical efficacy, the contributions to oncology management of this therapeutic will facilitate continuity of care, potentiate the patients adoption to treatment, adherence to their treatment regimen, inform patient clinician communication, lessen affective symptomatology (symptom cluster, severity, distress, or duration), reduce susceptibility to somatization, attenuate healthcare disparities and obstacles to care.
Cost effectiveness, individually, and collectively modulating these aforementioned clinical indicators will reduce the need for healthcare services beyond routine oncologic care, contain healthcare costs such as emergency room treat and release events (resulting from complications of cancer or its treatment, other comorbidities, or symptoms) and contribute to favorable patient performance status.
a.danu™ is educative, introspective and actionable. This personalized, participatory medical treatment is coupled with engaging digital technology, however, this treatment is not telehealth, does not utilize a virtual counselor, and is not health coaching.
Note, this multidimensional engagement combines digital technology with several accessory items. This Rx therapy is packaged as a spa-like kit and is provided to the patient in a small box that is approximately 8” wide x 2.5” high and 4” depth. This kit is shipped directly to the patient’s home or is provided from the hospital or practitioner’s venue for the patient to take home.
HCPCS: A9291
This prescription cognitive, emotional behavioral intervention is regulated through the FDA – CDRH division via the 510(k) class II pathway; software as a medical device.
a.danu™ is effectuated with HIPPA compliant applications and workflow utilization.
The tangible components are manufactured in the United States in accordance with cGMP guidelines. The cognitive behavioral component is termed software as a medical device (SaMD). This software architecture and app is developed in the United States, under ISO 13485 standards.
Note: this webpage provides a brief overview of the a.danu™ therapeutic. A more in-depth business to business dialogue is conducted via private communications.
a.danu™ is offered exclusively by Anu-Soma Healthcare LLC 2024.